PARP inhibitor

  • October 18, 2021  

    Results from Clinical Trial of Veliparib for People with Unmethylated Glioblastoma Bookmark

    George Lundberg, MD

    This scientific report from Neuro-Oncology outlines findings from a large, randomized clinical trial showing that the drug veliparib (a kind of drug known as a PARP inhibitor) added to radiotherapy and temozolomide did not improve progression-free survival in unmethylated glioblastoma.

    .

  • June 8, 2020  

    New Treatments for Ovarian Cancer in 2020

    Smruti Vidwans, PhD

    Women with ovarian cancer once relied solely on chemotherapy to treat their disease. However, in recent years, treatment options have expanded, and new options are also on the horizon. Read on to learn more about ovarian cancer and how it can be treated. What are the risk factors and symptoms of ovarian cancer? The American Cancer Society estimates that, in 2020, about 21,750 American… Read more »

  • August 22, 2018  

    PARP Inhibitor Talazoparib Benefit in BCRA+ Breast Cancer Bookmark

    Emma Shtivelman, PhD

    Excerpt from Medscape:

    “The now-published results from the EMBRACA study confirm that  talazoparib (Pfizer), a poly-adenosine diphosphate-ribose polymerase (PARP) inhibitor,  prolongs progression-free survival (PFS) in patients with advanced BCRA-positive breast cancer compared with single-agent chemotherapy alone, and that it also significantly improves quality of life.

    ” ‘This is the largest randomized trial in BRCA mutation carriers [ever undertaken] and demonstrates PARP efficacy,’ Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, told Medscape Medical News in an email.”

    Go to full article published by Medscape on Aug 15, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.